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Abstract 
Scope: Xantohumol is a hop derived prenylated flavonoid in beers and other beverages. 
Results of in vitro and animal studies indicate that it may have beneficial health effects due to 
its DNA protective, anti-inflammatory, antioxidant and phytoestrogenic properties. 
Furthermore, it was reported that it prevents obesity via interaction with the energy 
metabolism and may protect against cardiovascular diseases.  
Methods and Results: To find out if alterations of health related parameters are caused by 
XN in humans we realized an intervention trial in which the participants (n=22) consumed a 
XN supplemented drink (12 mg XN/P/d) for two weeks. We investigated the impact of intake 
of the flavonoid on DNA stability in single cell gel electrophoresis (SCGE) assays and on a 
variety of other health related biomarkers. We found no evidence for protection of the genetic 
material under standard conditions (which reflect single and double strand breaks) in 
lymphocytes, but a significant decrease of damage attributable to oxidatively damaged 
purines (FPG sensitive sites) and also protection of the cells towards ROS induced DNA 
damage. The assumption that the flavonoid causes DNA protection was confirmed in follow 
up trial in which the participants consumed pure XN. Also the excretion of 8-oxo-2´-desoxy 
guanosine (8oxodG) and 8-oxo-guanosine (8oxoGuo) in urine was significantly reduced. 
None of the other monitored parameters (oxLDL, cholesterol, HDL-C, LDL-C, MDA, 
progesterone, 17β-estradiol, blood glucose, triglycerol, FRAP, ORAC, urea, and CRP in 
plasma and 15F2t-Iso-P in urine) were altered.  
Conclusions: Taken together, our data show that low doses of XN protect humans against 
oxidative DNA damage. 
 
Words 254 (250 is allowed)  
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1. Introduction 
 
Xantohumol (XN) is a bioactive prenylated flavonoid which was isolated form hop extracts 
and beer (Stevens and Page 2004). Gerhäuser and co-worker tested this compound in a battery 
of in vitro assays which was developed for the screening of phytochemicals for putative 
cancer protective properties (Gerhauser 2005; Gerhauser et al. 2002). They found, that XN 
has highly promising properties and postulated that it may inhibit carcinogenesis at the 
initiation, promotion and progression (Gerhauser 2005). This assumption was based on 
findings which showed that XN inhibits the division of cancer cells (Plazar et al. 2007; Viegas 
et al. 2012), possesses anti-inflammatory properties (Lupinacci et al. 2009; Peluso et al. 2010) 
and phytoestrogenic activity (Coldham and Sauer 2001; Heyerick et al. 2006), acts as a potent 
antioxidant (Pinto et al. 2012; Stevens and Page 2004) and protects DNA against chemically 
induced damage (Filipic et al. 2009). 
Evidence for these effects came initially from in vitro experiments and it was found 
that XN is effective in some of these models at very low concentrations. Subsequently, results 
from a few animal studies became available which support the assumption of cancer 
protective properties of the flavonoid. We showed in a recent investigation that XN prevents 
chemical induction of DNA damage and formation of preneoplastic lesions in livers and 
colons of rats (Ferk et al. 2010). Furthermore, it was found that it inhibits angiogenesis and 
oxidative stress (Costa et al. 2013), and reduces obesity in laboratory animals (Kirkwood et al. 
2013). 
Aim of the present study was to find out if beneficial effects can be expected also in 
humans. Therefore, we performed the first controlled intervention trial with XN and 
investigated if consumption of the flavonoid prevents DNA damage, which plays a key role in 
the etiology of cancer and other diseases (Kryston et al. 2011). Additionally, we monitored a 
variety of health related biomarkers which reflect oxidative stress, the hormonal status, 
osteogenesis, inflammations and glucose and lipid metabolism since it was postulated on the 
basis of results obtained in vitro with cultured cells and with rodents that XN may cause 
beneficial health effects due to its phytoestrogenic properties, reduce the risks for cardio-
vascular disease (CVD) and help to control the body weight (Liu et al. 2015). The participants 
consumed in the main study a XN containing non-alcoholic beverage or a placebo. The 
amount of XN which was given to each individual (12mg/P/d) is equal to that which was used 
in a previous animal study (Ferk et al. 2010) and is contained (30-690 µg/L) in several liters 
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of XN rich beer types (Stevens and Page 2004) and in one liter of the refreshment dink which 
we used. 
Alterations of the DNA stability were measured in single cell gel electrophoresis 
(SCGE) assays which are based on the determination of DNA migration in an electric field 
and are increasing in human intervention studies (Collins et al. 2014; Dusinska and Collins 
2008). The measurements were conducted under standard conditions (which reflect formation 
of single and double strand breaks and apurinic sites); with lesion specific enzymes which 
enable the assessment of endogenously formed oxidatively damaged DNA bases and after 
ROS (H2O2) treatment of the lymphocytes. Additionally, 8-oxo-guanosine (8-oxodGuo) and 
8-oxo-2´-desoxy guanosine (8-oxodG) levels were measured in urine as additional markers of 
oxidative damage (Weimann et al. 2012). 
Parameters of the redox status which were determined in the participants before and 
after consumption of the XN drink included isoprostane (15-F2t-IsoP) in urine, oxidized low-
density lipoprotein (oxLDL), the oxygen radical absorbance capacity (ORAC), 
malondialdehyde levels (MDA) and the ferric reducing ability (FRAP) in plasma (Knasmuller 
et al. 2008). These parameters were monitored as Gerhäuser et al. (2002) found that XN is a 
potent scavenger of peroxyl-and hydroxylradicals under in vitro conditions. C-reactive protein 
was monitored as a marker for inflammations (Du Clos 2013) and for increased cancer risks 
(Ansar and Ghosh 2013). It was shown earlier that the flavonoid reduces inflammations in 
diabetic rats (Costa et al. 2013) and inhibits the expression of pro-inflammatory genes in 
human and rat derived liver cells (Dorn et al. 2010). Changes of the hormonal status were 
monitored by determination of the progesterone and 17β-estradiol concentration in the blood 
of the participants. As mentioned above, evidence for phytoestogenic propeties were obtained 
in in vitro experiments with different cell lines (Gerhauser et al. 2002; Overk et al. 2005). 
Alkaline phosphatase (ALP) activity was determined in serum. This enzyme is controlled by 
estrogen receptors (ERs) receptor and dephosophorylates proteins involved in cell growth, 
differentiation apoptosis and cell migration and it was shown by Guerreiro and coworkers 
(2007) that XN decreases its expression in MCF-7 cells. Furthermore, changes of the glucose 
and lipid metabolism were monitored (glucose, triglycerol, cholesterol, LDL-cholesterol and 
HDL-cholesterol in plasma) as a number of investigations indicate that XN interacts with the 
glucose and lipid metabolism (Kirkwood et al. 2013; Yui et al. 2014). 
 To prove that alterations of individual markers are caused by the flavonoid itself and 
not by other components of the drink (roast malt extract and malic acid), a small follow up 
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study was realized in which the participants (n=10) consumed an identical amount of pure XN 
as in the main study. 
 
2. Materials and methods 
 
2.1. Composition of the XN drink 
The XN supplemented drink (commercially not available) which was tested in the present 
study was provided by TA-XAN Company (www.xan.com). 1000 mL of the beverage 
contained 12.0 mg of the flavonoid, 1.0 g/L roast malt extract, 40.0 g/L sugar, and 0.042 g/L 
malic acid. The placebo drink which was given contained identical amounts of the latter 
components but no XN. 
 
2.2. Recruitment of the participants 
 
The study was approved by the Ethical Commission of the Medical University of Vienna 
(EKNr.: 341/2010), and informed consent was obtained from all participants. In total, 22 
individuals (11 females and 11 males) participated in the study with the beverage. All of them 
were healthy non-smokers who consumed a mixed diet. Two weeks before and during the 
intervention they did not consume dietary supplements and pharmaceuticals (except 
contraceptives). Furthermore, they were asked to avoid consumption of beer and foods which 
contain high levels of flavonoids and to abstain from exhausting physical exercise which may 
affect DNA stability (Reichhold et al. 2009), as well as the redox status one week before and 
during the intervention period and during the washout phase. The demographic data of the 
participants are listed in Table 1. 
 
      Table 1 
 
Participants of the second trial (n=10, 4 females and 6 males) fulfilled the same 
inclusion criteria.  
 
2.3. Study design and sampling 
 
The design of the intervention trial with the XN drink is depicted in Figure 1. The trial had a 
cross over design which has the advantage that seasonal effects which were observed in some 
Commentato [a1]: not sure if correct ref ther is 3 article - 
but one state no relation so? 
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SCGE studies can be avoided (Nersesyan et al. 2009).The participants consumed every day 
either one liter of the XN supplemented drink or an equivalent amount of a XN free placebo 
in the morning 4 hours prior to the blood draw. Urine and blood samples were collected at the 
start, during (4h, 3d, 7d) and the end of the intervention period (14d) and after a wash out 
phase (14d).  
The follow up study was also an intervention trial. The participants consumed tablets 
containing pure XN (12.0 mg/P/d) over a period of 14 days. Blood samples were collected 
before and after the intervention. 
 24h urine samples were collected in the main study at the start and at the end of the 
study and were stored deep frozen at -80 ºC. Blood samples were collected after different time 
points (start, 4h, 3d, 7d, 14d) in heparinized tubes (Becton-Dickinson, Plymouth, UK). After 
centrifugation (760 g, 10 min, 4 ºC), the plasma samples were aliquoted and stored at -80 ºC.  
Lymphocytes were isolated with Histopaque-1077 (Sigma-Aldrich, Steinheim, 
Germany) according to the instructions of the manufacturer. Subsequently, suspensions of the 
cells were aliquoted in Biofreeze (Biochrom AG, Berlin, Germany) and stored in liquid 
nitrogen. 
 Before and during the study, the pulse frequencies, blood pressure and body weights 
of the participants were recorded. Additionally, information concerning the impact of the 
consumption of the beverage and of the pure flavonoid on the health status was collected via 
questionnaires. 
 
      Figure 1 
 
2.4. Determination of xanthohumol concentrations in plasma 
 
The concentration of XN in plasma was determined with a Dionex “UltiMate 3000” system 
(Dionex Corp., Sunnyvale, CA). The column oven was set at 35°C and the UV-Detector at 
380 nm. Briefly, after the addition of 500 µL of acetonitril to 250.0 µL of plasma, the samples 
were centrifuged (5000g, 5 min, 4°C), 80.0 µL of the sample was injected onto the HPLC 
column. Separation of XN was carried out using a Hypersil BDS-C18 column (5 µm, 250 x 
4.6 mm I.D., Astmoor, England) preceded by a Hypersil BDS-C18 pre-column (5 µm, 10 x 
4.6 mm I.D.) at a flow rate of 1 mL/min. The mobile phase consisted of a continuous linear 
gradient, mixed from 10 mM ammonium acetate/acetic acid buffer, pH 5.0 (mobile phase A) 
and methanol and acetonitril (mobile phase B). The gradient ranged between 20 % B (0 min) 
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and 80 % at 20 min, kept constant at 80 % until 25 min and finally decreased linearly to 20 % 
at 27 min. The columns were allowed to re-equilibrate for 9 min between runs. Linear 
calibration curves were established from the peak areas of XN to the external standard by 
spiking drug-free human serum with standard solutions of XN (final concentrations ranging 
from 0.005 µg to 10.0 µL/mL). The limit of quantification for XN was 0.005 µg/mL with 
coefficients of accuracy and precision < 9%.  
 
2.5. Determination of DNA and RNA damage  
 
2.5.1. SCGE assays with human lymphocytes 
 The experiments were carried out according to the guidelines for SCGE experiments 
(Tice et al. 2000). Frozen cells were thawed and centrifuged (8 min, 110g) twice in 
phosphate-buffered saline (PBS, pH 7.4). The viability of the thawed cells was determined in 
each experiment with the trypan blue (0.4%) dye exclusion technique (Lindl and Bauer 1994) 
with an improved Neubauer hemocytometer (Paul Marienfeld GmbH, Lauda-Königshofen, 
Germany). DNA damage was only analyzed in cells from samples in which the vitality was ≥ 
80% as acute toxic effects may cause false positive results (Henderson et al. 1998). The cells 
were mixed with 0.5% LMPA and transferred to agarose coated slides (1.0% NMPA). For 
comet assay standard condition (SC), after lysis (pH 10.0), electrophoresis was carried out (30 
min, 300 mA, 1.0 V/cm, at 4 ◦C, pH > 13) under alkaline conditions. Subsequently, the slides 
were neutralized and air dried slides were stained with ethidium bromide (20.0 µg/mL, 
Sigma-Aldrich, Steinheim, Germany). 
 Additionally, experiments were conducted in which intact cells were treated with H2O2 
(on ice). After exposure to 50 µM for 5 min, slides were rinsed with PBS and further 
processed as described above. Control slides were exposed in these experiments to PBS. 
To determine formation of oxidatively damaged DNA bases, the nuclei were exposed 
after lysis to formamidopyrimidine glycosylase (FPG, Sigma-Aldrich, Steinheim, Germany) 
or to endonuclease III (ENDO III, Sigma-Aldrich, Steinheim, Germany). To establish the 
optimal amounts of the enzymes, calibration experiments were carried out with blood cells 
from 3 donors according to the protocol of Collins et al. (1997). After lysis, the slides were 
washed twice with enzyme reaction buffer (pH 8.0) for 8 min. Subsequently, the nuclei were 
treated with 50 µl of enzyme solutions or with the enzyme buffers. The incubation time for 
FPG was 30 min and for ENDOIII 45 min at 37 ◦C respectively. After the treatment, 
electrophoresis was carried out under standard conditions (30 min, 300 mA, 1.0 V/cm, at 4 ◦C, 
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pH > 13 for details see Collins and Dusinska, (2002). In all these experiments, parallel 
measurements were included, in which the nuclei were treated with the enzyme reaction 
buffers only. After lysis and electrophoresis, slides were evaluated as described above. 
 From each participant, three slides were prepared per experimental point and from 
each slide, 50 cells were evaluated. Slides were examined under a fluorescence microscope 
(Nikon EFD-3, Tokyo, Japan) using 25-fold magnification. DNA migration was determined 
with a computer aided comet assay image analysis system (Comet Assay IV, Perceptive 
Instruments, UK). 
 
2.5.2. Measurement of 8-oxo-2´-desoxy guanosine and 8-oxo-guanosine (8-OHdG and 
8oxoGuo) in urine 
8oxodG and 8oxoGuo were determined in urine. Briefly, a chromatographic separation was 
conducted on an Acquity UPLC system (Waters, MA, USA), using an Acquity UPLC BEH 
Shield RP18 column (1.7 µm, 2.1 x 100 mm) and a mobile phase of ammonium acetate 
(2.5 mM/L, pH 5) and acetonitrile. MS/MS detection was conducted with API 3000 triple 
quadrupole mass spectrometer (Sciex, Toronto, Canada) using gel electro spray ionization. As 
internal standards 15N5-8oxoGuo and 15N5-8oxodG were applied (Henriksen et al. 2009).  
 
2.6. Determination of biochemical parameters which reflect the redox status  
 
2.6.1. Ferric reducing ability of plasma (FRAP) 
The FRAP assay is based on the measurement of the reduction of a ferric tripyridyltriazine 
complex (Fe3+) to a ferrous complex (Fe2+) at pH 3.6. Changes in absorbance are directly 
related to the reducing power of antioxidants present in the samples. The measurements were 
conducted as described by Benzie and Strain (1996). 
 
2.6.2. 15-Isoprostane F2t 
15-Isoprostane F2t was determined in urine with a commercially available ELISA kit (Oxford, 
MI, USA) according to the instructions of the manufacturers. Urinary creatinine was 
determined by Jaffe´ procedure (Bartels and Cikes 1969). 
 
2.6.3. Malondialdehyde (MDA)  
MDA levels were determined in plasma according to the method of Ramel et al., (2004). The 
samples were neutralized after heating (60 min, 100 ◦C) with methanol/NaOH, centrifuged 
(3 min, 3000 rpm); subsequently MDA was measured with HPLC (excitation: λ = 532 nm, 
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emission: λ = 563 nm, LaChrom Merck Hitachi Chromatography system, Japan). Each sample 
was measured in duplicate. 
 
2.6. 4 Oxygen radical absorbance capacity (ORAC)  
The ORAC assay was conducted with plasma samples and is based on the inhibition of the 
peroxylradical induced oxidation which is triggered by thermal decomposition of the azo-
compound (2,2`-azo-bis 2-amidino-propane dihydrochloride). The measurements were 
performed according to the protocol of Cao et al. (1999).  
 
2.6.5. Oxidized low-density lipoprotein (oxLDL)  
Plasma oxLDL concentrations were measured in plasma with a commercially available 
ELISA kit (Mercodia AB, Uppsala, Sweden) according to the instructions of the 
manufacturer. Absorbance of the samples and of the standards was determined with a 
fluorimeter (BMG Lab Technologies, Offenburg, Germany). 
 
2.7. Parameters related to energy metabolism 
 
2.7.1. Glucose  
Glucose was measured enzymatically according to the protocol of Keilin and Hartree (1948). 
This method based on the oxidation of glucose by highly purified glucose oxidase. 
 
2.7.2. Cholesterol and lipoproteins 
Cholesterol and triglycerol were determined to an enzymatic colorimetric method according 
to Sperry and Brand 1943, see also Bucolo and David (1973)) with a chemical analyzer 
(AVIDA 2400, Siemens Healthcare Diagnostics GmbH, Schwalbach am Taunus, Germany). 
HDL-C was measured by a turbidimetric immunoassay (Bachorik and Cloey 1989) LDL-C 
was estimated as described by Friedewald et al. (1972). 
 
2.8. Parameters associated with inflammations 
 
2.8.1. C-reactive protein (CRP) 
CRP was monitored in plasma with a turbidimetric immunoassay according to Sisman et al., 
(2007).The measurements were conducted with an Olympus OSR6299 automated analyzer 
(Melville, NY, US). 
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2.8.2. Urea 
Urea was determined enzymatically by use of ureases described by Wilcox et al. (1966).The 
measurement is based on a colorimetric method. The measurements were conducted with an 
automated analyzer (AVIDA 2400, Siemens Healthcare Diagnostics GmbH, Schwalbach am 
Taunus, Germany). All reagents were purchased from Siemens Healthcare Diagnostics. 
 
2.8. Hormonal status and hormone associated parameters 
 
2.8.1. Estradiol and progesterone 
Serum 17β-estradiol and progesterone levels were measured with the ADVIA Centaur 
automated system (Siemens Healthcare Diagnostics GmbH, Schwalbach am Taunus, 
Germany) with chemiluminescence immunoassays (CLIA) according to the method of 
(Nisbet and Jomain 1987). 
 
2.8.2. Alkaline phosphatase and osteocalcin 
Serum alkaline phosphatase (ALP) and osteocalcin (OC) activities were determined with 
electrochemiluminescence immunoassays (ECLIA) according to the method of (Ref.).  
 
2.9. Statistical analyses 
 
2.9.1. Single cell gel electrophoresis assays 
The means and S.D. of % DNA in the comet tails of the different groups were calculated on 
the basis of the results of the individual measurements. The extent of DNA migration 
attributable to FPG and ENDO III sensitive sites was calculated by subtraction of the 
corresponding enzyme buffer values which were determined in all experiments. Comparisons 
of groups were done by ANOVA based on the means of three slides. Post hoc comparisons 
between groups (placebo vs. XN) were assessed by one way ANOVA followed by Dunnett’s 
test. 
 
2.9.2. Other biochemical parameters  
All biochemical parameters were measured in duplicate and statistical significance was 
analyzed by use of ANOVA followed by Dunnett’s test. For all comparisons, p-values ≤ 0.05 
were considered as significant. Statistical analyses were performed using Graphpad Prism 4.0 
(Graphpad Software, San Diego, CA, USA). 
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3. Results 
 
3.1. Compliance and impact of consumption of the beverage on the overall health status  
The consumption of the beverage did not cause health problems in the participants according 
to the information collected with the questionnaires. All participants finished the study. Body 
weights, blood pressure and pulse were measured at the beginning, during and the end of the 
intervention trial. Values which were recorded at the start and at the end of the intervention 
with the XN containing drink are listed in Table 1. It can be seen that no significant changes 
of the different parameters were found.  
 
Table 1 
 
3.2. Determination of XN concentrations in plasma 
XN was detectable in plasma up to 4h after consumption of the beverage (average 
concentration in the intervention group 17.5 ± 10.8 ng/mL. 
 
 
3.3. Alterations of DNA stability 
The results of SCGE assays with lymphocytes are summarized in Figures 2A-D. It can 
be seen that no significant alteration of comet formation was seen when the cells were 
analyzed under standard conditions which reflect single and double strand breaks. However, 
treatment of the nuclei with FPG lead to a significant decrease of DNA migration. The effects 
which were observed with FPG increased with duration of the intervention period. After two 
weeks of continuous consumption of the XN drink, the extent of DNA migration was 
significantly reduced by 33% (p < 0.001, Fig. 2C). On the contrary no alterations of DNA 
migration were seen after treatment of the nuclei with the second lesion specific enzyme 
ENDO III (Fig. 2D).  
The results which were obtained after exposure of the cells to ROS are depicted in 
Figure 2B. Exposure to H2O2 led to a pronounced (ca. 2-fold) increase of DNA damage over 
the background levels. After consumption of the XN drink, a decrease of the extent of H2O2 
induced comet formation was observed i.e. a significant reduction of the % DNA in the tails 
by 53% (p < 0.05) was recorded after two weeks. The protective effects (decreased formation 
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of FPG sensitive sites which reflect oxidatively damaged purines and decreased sensitivity 
towards ROS induced DNA damage) disappeared at the end of the washout period.   
 Figures 2A-D show also the results which were obtained with the placebo drink; it can 
be seen that no significant alterations were found in the different experimental series. 
 
      Fig. 2A-D 
 
 Similar effects were detected with the pure XN tablets in the follow up intervention 
trial. Significant protection of the DNA damage was seen after 14 days consumption of the 
compound after treatment with FPG (reduction of comet formation by 39%, p < 0.001) and 
H2O2 (reduction of comet formation by 28%, p < 0.05). 
 
      Table 4 
 
 To find out, if consumption of the XN drink has also an impact on the excretion of 
oxidized DNA bases, additional measurements of 8oxodG and 8oxoGuo were conducted with 
urine samples which were collected from the participants at the start and at the end of the 
intervention phase. A significant reduction of the concentrations of both parameters was 
observed at the end of the study. The level of 8oxodG decreased from 21.7 ± 13.7 to 12.2 ± 
5.9 nM. Also the levels of 8oxoGuo declined after consumption of the XN drink from 27.5 
±18.0 to 16.2 ± 7.0 nM (all values are means ± SD of results obtained with samples from 22 
participants). 
 
      Table 3 
 
3.4. Health related markers and biochemical parameters 
 
The results of measurements of the different biochemical parameters are summarized in 
Tables 2-3. It can be seen that none of them was significantly altered after consumption of the 
flavonoid.  
 
      Table 2-3 
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4. Discussion 
 
This article describes the results of the first placebo controlled human intervention trial in 
which the impact of consumption of the flavonoid on a health related biomarkers was 
monitored. All earlier investigation with humans concerned the pharmacokinetics and tissue 
distribution of the compound (Bolca et al. 2010; Legette et al. 2013; van Breemen et al. 
2014). The daily dose which was consumed by the participants in the present study is in the 
same order of magnitude as the levels which are reached after consumption of XN rich beers 
and of non-alcoholic refreshment drinks. Taken together, we found clear evidence for 
pronounced protection of the genetic material against oxidative DNA damage. However, other 
health related biomarkers which reflect changes of the energy and lipid metabolism, 
inflammations and the hormonal status were not significantly altered at the end of the 
intervention period. 
 As described in the results section (Fig. 2) we observed pronounced reduction of FPG 
sensitive lesions after the intervention (by 33%). Furthermore, we detected also a decrease of 
ROS (H2O2) induced comet formation (by 53%). All these effects increased with the duration 
of the intervention time. Other endpoints for DNA damage, i.e. comet formation under 
standard condition reflecting single and double strand breaks and DNA migration attributable 
to ENDO III sensitive sites which are caused by oxidatively damaged pyrimidines were not 
affected by XN. No effects were seen in the placebo group at any time point and the findings 
which were obtained in the follow up study with XN pills proof that the protective effects are 
caused by the flavonoid and not by other components of the beverage which was consumed in 
the main trial. The results of the FPG experiments which are indicative for prevention of 
formation of oxidized purine bases are supported by the findings which were obtained in 
HPLC measurements with urine samples. The results show clearly that the intake of XN leads 
to substantial reduction of the excretion of 8oxoGuo and 8oxodG. 
 It is notable that DNA protective effects of XN were reported earlier by Plazar et al., 
(Plazar et al. 2008; 2007) who performed in vitro experiments with liver slices and a human 
derived liver cell line (HepG2). They found reduced comet formation with t-butyl-
hydroperoxide (t-BOOH) when they added low doses (0.01 µM) of XN (3.5-35.4 ng/mL) 
which were similar to the serum levels detected in our present study with the participants 
(17.5 ng/mL). These findings are of interest in regard to the present study as t-BOOH causes 
DNA damage via formation of ROS (Aguirre et al. 1998). The same group published 
additional findings which indicate that XN protects also against DNA damage caused by 
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genotoxic carcinogens such as heterocyclic aromatic amines and polycyclic aromatic 
hydrocarbons (Kac et al. 2008; Plazar et al. 2007; Viegas et al. 2012); also in these 
experiments, protective effects were seen with low concentrations. 
Two modes of action may account for the prevention of oxidative DNA damage by 
XN, namely direct scavenging of radicals or (indirect) induction of ROS protective enzymes. 
Several in vitro studies show that XN prevents formation of oxLDL, reduces the ORAC and 
inactivates NO as well as O2 radicals (Gerhauser 2005; Gerhauser et al. 2002). These and 
other in vitro experiments were conducted with models which do not reflect the induction of 
antioxidant enzymes and were carried out with concentrations which exceed the serum levels 
of the flavonoid which we detected in the blood of the participants after consumption of the 
XN drink by two to three orders of magnitude. These findings indicate that XN is (like many 
other flavonoids) able to inactivate reactive ROS via scavenging. However, the doses which 
were required to prevent induction of oxidative DNA damage by t-BOOH in vitro (see above) 
were much lower (see above) and protective effects were only seen when the indicator cells 
were exposed for several hours to XN before treatment with the genotoxin but not when a 
simultaneous treatment protocol was used (Plazar et al 2007). Since antioxidant enzymes are 
represented in inducible form in the indicator cells (HepG2) which were used in this study 
(Padgett et al. 2013) it is likely, that the DNA protective effects which were detected are due 
their up-regulation. In this context, it is notable that induction of ROS protective enzymes 
(superoxide dismutase, glutathione S-transferase and glutathione peroxidase) and of 
glutathione (which is a potent ROS scavenger) was found in in vivo experiments with rats and 
also with tupaias after oral administration of XN (Pinto et al. 2012; Yang et al. 2013) These 
effects were seen in the fewer study with doses which are sensitive to wards is the present 
investigation with humans. Recently, a paper was published by Yao and co-workers (2015) 
who found that XN is in neuronal cells a potent activator of Nrf2 which controls the 
transcription of a variety of phase II and antioxidant enzymes; this observation could explain 
the pronounced ROS protective properties of the flavonoid.   
 The SCGE assay with lesion specific enzymes and/or ROS (H2O2) treatment has been 
used in a number of earlier human intervention trials (Collins et al. 2014; Moller and Loft 
2002; Moller and Loft 2004; Nersesyan et al. 2009). Protective effects were seen with 
several foods, beverages also with selected vitamins and other bioactive food constituents. 
Comparisons of the present results with findings of earlier trials show that XN is extremely 
effective in regard to prevention of oxidative DNA damage. For example, no evidence for 
protective effects was seen in a study with resveratrol which had a similar design (Heger et al. 
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2012). With vitamins C and E, reduction of comet formation as a consequence of ROS (H2O2) 
treatment was seen only with dose levels which were substantially (10- to 100-fold) higher 
than the XN doses which were consumed by the participants in the present investigation (Ferk 
et al. 2010; Hartmann et al. 1995; Kac et al. 2008; Moller and Loft 2002; Moller and Loft 
2004; Moller et al. 2004). The only compound which has a similar activity as XN is gallic 
acid which reduced formation of ENDO III and FPG sensitive sites in human lymphocytes 
after consumption of low doses (Ferk et al. 2011)  
 As mentioned above, it was postulated that XN may cause beneficial effects in humans 
due to its phytoestrogenic activities and that it may reduce CVD and cause weight loss due to 
reduced uptake of glucose from the GI-tract via changes of the lipid metabolism and 
prevention of inflammations (Liu et al. 2015). It can be seen in Table 2 that we found no 
evidence for such effects in the present experiments. The main reasons for the discrepancy of 
our results with findings of older investigations are most likely differences in the dosage. 
Dose used in present study was 0.17 mg/kg b. w./day in human which corresponds to dose of 
1.05 mg/kg b.w./day in mice (Nozawa et al., 2005). The daily dose which was required to 
cause a significant reduction of the plasma glucose levels in rats was 16.9 mg/kg b.w./day 
while lower amounts (equivalent to 5.64 and 1.86 mg/kg b.w./day) were not effective (Legette 
et al. 2013). Also in in vitro experiments high concentrations were required to cause effects. 
For example, in regard to activation of the farnesoid receptor (which plays a key role in lipid 
and glucose metabolism), a concentration of 5 µg/mL was found to cause a clear effect 
(Nozawa 2005). This dose is 300-fold higher than the peak plasma concentrations (17.5 
ng/mL) which were detected in the participants of the present study. In regard to alterations of 
the hormonal status which were attributed to the phytoestrogenic properties of XN and other 
structurally related hop flavonoids, the situation is similar, i.e. the doses which were required 
to cause effects in human derived breast cancer cells were higher than the levels which were 
found in the serum of the participants (Gerhauser et al. 2002). As shown in Table 3 no 
alterations of the progesteron and 17ß-estradiol concentrations were found at the end of the 
intervention phase. Since estrogens have an impact on bone formation it was hypothesized 
that prenylated hop may prevent osteoporosis. Furthermore, also other mechanisms were 
discussed which they may affect this process (for review see Liu et al. (2015)). Indeed, it was 
found that XN affects osteoblast differentiation and induction of ALP which is a marker for 
osteogenesis in several studies (Effenberger et al. 2005; Gerhauser et al. 2002; Jeong et al. 
2011). These effects were detected under in vitro conditions with XN doses which are at least 
five-fold higher than the serum levels of the participants in our study. This discrepancy 
Eliminato: For example, reduction of glucose and 
triglyceride levels in plasma we seen in feeding experiments 
with mice when the uptake levels of the animals were 112 
mg/kg/d (Nozawa et al 2005), in another representative 
experiments, t
Eliminato: mice 
Eliminato: 119 
Eliminato: 400 
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provides a plausible explanation for the lack of an effect in the present investigation. In regard 
to the impact of XN on breast cancer risk which is affected by estrogens, it is notable that 
Bolca et al. (2010) published the results of a human study which concerned the distribution of 
prenylflavonoids in breast tissue; the authors come to the conclusion that it is unlikely that 
consumption of low levels (6.12 mg/P/d) elicit responses which are mediated via estrogen 
receptors and are relevant for breast carcinogenesis.  
 The most interesting result of the present study is the observation of protection of the 
genetic material against oxidative damage (see Fig. 2). Although no data from human studies 
are available which concern the associations between oxidation of DNA bases and cancer 
risks, results which were obtained with genetically modified animals show that mutations in 
genes encoding for enzymes which are involved in the repair of oxidatively induced DNA 
damage lead to tumors in different organs (Russo et al. 2009). Furthermore, it is also notable, 
that increased cancer rates were seen in humans with polymorphisms in such genes 
(Dizdaroglu 2012; Kryston et al. 2011). Another relevant area, apart from cancer are 
neurological disorders since several recent findings indicate that oxidative DNA damage may 
play a role in the etiology of neurodegenerative diseases (NDs) (Thanan et al. 2015). The fact 
that XN was found extremely active in regard to protection of humans makes it a promising 
candidate for the chemoprevention of cancer and NDs and further investigations in this 
direction should be realized.  
 
Conflict of interest 
The authors declare that they do not have anything to disclose regarding funding or conflict of 
interest. 
 
 
Acknowledgments  
The authors are thankful to MDs B. Ghanim and A. Hoda for help concerning the collection 
of blood samples, to TA-XAN AG for providing us with the experimental beverages and to 
Norbert Frank (German Cancer Research Center, Heidelberg) for help in the realization of the 
biochemical measurements. 
The experimental work was partly supported by TA-XAN AG. 
  
17 
 
Legends for figures 
Figure1. Design of the intervention trial. Blood and urine samples were collected after 
different time points. 
 
Figure 2A-D. Impact of consumption of the XN supplemented beverage (white bars) and of a 
XN free (placebo) drink (black bars) on DNA damage in peripheral lymphocytes. The 
participants (n =22) consumed 1L of the beverages over a period of 14 days. Blood and urine 
samples were collected before, during and after the intervention (wash out) (for details see 
Fig. 1). DNA migration was measured in SCGE assays under standard electrophoresis 
conditions (2A), after exposure of intact cells to ROS (50.0 µM H2O2) on ice for 5 min (2B), 
after treatment of the nuclei with FPG (2C) and ENDO III (2D). For each experimental point, 
three slides were made in parallel and 50 cells were analyzed from each slide. Bars show 
means ± SD of results which were obtained with 22 individuals. In the case of the results 
obtained with lesion specific enzymes, the corresponding buffer values were subtracted. Stars 
indicate statistical significance (p ≤ 0.05, ANOVA). 
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Table 1. Demographic data of the participants. a 
 
  Start   Placebo  
(14d) 
  
XN 
supplemented 
drink (14d) 
 
Parameters Males 
(n=11) 
Females 
(n=11) 
All 
(n=22) 
Males 
(n=11) 
Females 
(n=11) 
All 
(n=22) 
Males 
(n=11) 
Females 
(n=11) 
All 
(n=22) 
Body weight (kg) 80.8 ± 11.3 66.2 ± 9.9 73.5 ± 12.8 80.6 ± 11.2 66.1 ± 9.7 73.4 ± 12.6 81.3 ±11.7 66.3 ±10.1 73.8 ±13.2 
BMI (kg/m2) 25.0 ± 3.1 24.2 ± 3.6 24.6 ± 3.3 25.3 ±2.9 23.6 ± 3.9 24.4 ± 3.2 25.2 ± 2.6 25.0 ± 3.1 25.1 ±2.8 
Age (y) 25.0 ± 2.9 27.3 ± 4.3 26.1 ± 4.3 25.0 ± 2.9 27.3 ± 4.3 26.1 ± 4.3 25.0 ± 2.9 27.3 ± 4.3 26.1 ± 4.3 
SBP (mmHg)  
DBP (mmHg) 
135.3 ± 14.9   
77.0 ± 10.7 
118.1 ± 12.9  
77.5 ± 7.3 
126.7 ± 16.2  
77.3 ± 9.0 
133.0  ± 11.4 
74.1 ± 7.7 
116.1 ± 10.1 
74.4 ± 9.0 
124.5 ± 13.6 
74.3 ± 8.2 
134 ± 12.9 
77.0  ± 7.7 
116.5 ± 10.8 
75.0 ± 6.5 
125.3 ± 14.6 
76.2 ± 7.1 
Pulse (min.) 80.2 ± 11.8 82.9 ± 13.4 81.5 ± 12.4 79.8 ± 10.1 76.7 ± 11.14 78.2 ± 10.4 82.0 ± 13.4 77.9 ± 8.4 80.0 ± 11.1 
 
a Numbers indicate means ± S.D. 
BMI, Body Mass Index; DBP, diastolic blood pressure; SBP, systolic blood pressure 
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Table 2. Biochemical parameters I. a 
 
Parameters Units   Placebo 
 
 
    XN 
Supplemented 
drink 
  
  Start 4h 3d 7d 14d Wash out 4h 3d 7d 14d 
Redox status            
FRAP µM/L 335.9 ± 109.4 395.8 ± 126.2 367.8 ± 111.7 376.3 ± 69.3 366.6 ± 150 372.0 ± 124.0 361.6 ± 88.63 337.6 ± 72.3 353.8 ± 109.6 351. 8 ± 118.8 
MDA µM/L 1.4 ± 0.7 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 1.3 ± 0.5 1.5 ± 0.5 1.5 ± 0.4 1.3 ± 0.5 1.4 ± 0.5 1.3 ± 0.5 
ORAC mM TE/L 3.5 ± 1.1 3.9 ± 0.4 3.8 ± 0.4 3.4 ± 0.6 3.7 ± 0.9 3.1 ± 0.5 4.0 ± 0.7 3.8 ± 0.3 3.5 ± 0.5 3.6 ± 0.4 
OxLDL U/L 54.3 ± 24.3 43.4 ± 13.9 59.2 ± 27.4 52.2 ± 35.7 38.1 ± 14.1 52.5 ± 33.1 45.2 ± 18.0 55.6 ± 17.6 45.3 ± 17.9 50.8 ± 17.7 
Glucose  
& lipid status 
           
Glucose mg/dL 84.3 ± 23.0 93.0 ± 17.0 90.0 ± 15.2 86.3 ± 13.2 80.8 ± 19.8 86.8 ± 20.7 91.8 ± 16.2 95.3 ± 13.2 84.8 ± 13.8 85.0 ± 12.4 
Triglycerol mg/dL 91.3 ± 62.0 122.4 ± 50.9 109.3 ± 63.1 100.9 ± 52.5 111.6 ± 76.5 100.2 ± 51.7 120.1 ± 49.3 95.9 ± 38.1 102.1 ± 53.2 124.4 ± 50.5 
LDL-C mg/dL 89.0 ± 32.18 87.6 ± 22.1 90.0 ± 19.9 88.4 ± 19.2 82.7 ± 25.1 87.0 ± 19.7 89.6 ± 25.2 90.9 ± 23.0 89.1 ± 22.1 85.0 ±27.8 
 
HDL-C mg/dL 54.0 ± 19.6 58.1 ± 12.2 56.9 ± 14.2 56.5 ±13.2 52.1 ± 18.1 53.7 ± 17.1 54.0 ±13.7 54.2 ± 13.3 56.2 ± 14.1 57.2 ± 14.6 
Cholesterol mg/dL 161.4 ± 50.4 170.3 ± 26.9 168.8 ± 30.8 165.2 ± 28.4 157.3 ± 46.39 160.9 ± 31.8 166.5 ± 31.1 165.0 ± 26.7 167.4 ± 29.8 171.6 ± 30.0 
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Table 2. Continued  
 
Parameters Units   Placebo 
 
    XN 
supplemented 
drink 
  
Inflammation 
status 
 Start 4h 3d 7d 14d Wash out 4h 3d 7d 14d 
Urea mg/dL 26.0 ± 8.5 25.5 ± 6.8 24.6 ± 6.0 25.9 ± 4.3 21.4 ± 6.4 25.6 ± 8.3 25.4 ± 6.2 23.0 ± 5.8 25.3 ± 
5.7 
23.4 ± 8.3 
CRP mg/dL 0.2 ± 0.3 0.2 ± 0.3 0.1 ± 0.2 0.2 ± 0.2 0.1 ± 0.2 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.7 0.1 ± 
0.2 
0.1 ± 0.2 
 
a Values represent means ± S.D. All measurements were carried out in plasma and were measured in duplicat. Laboratory diagnosis for reference ranges are according to Klinikleitfaden, 
Labordiagnostik, 2007: glucose (70-100 mg/dL) triglycerol (< 150 mg/dL); LDL-C (70-100 mg/dL); HDL-C (40-60 mg/dL); cholesterol (< 200 mg/dL); Urea (10-50 mg/dL); CRP (< 0.5 
mg/dL).  
CRP, C-reactive protein; FRAP, ferric reducing ability of plasma; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MDA, malondialdehyde; ORAC, 
oxygen radical absorbance capacity; oxLDL, oxidized low-density lipoprotein; TE, trolox equivalent. 
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Table 3. Biochemical parameters II. a 
 
Parameters Samples Units  Start    XN  
Supplemented drink 
(14d) 
 
   Males (n=11) Females (n=11) All (n=22)  Males (n=11) Females (n=11) All (n=22) 
Hormononal status &  
hormone related parameter 
serum         
Alkaline phosphatase  U/L 60.7 ± 11.5 85.8 ± 14.5 73.9 ± 18.2  64.8 ± 14.4 83.0 ± 13.8 73.9 ± 16.6 
Osteocalcin  ng/mL 20.3 ± 5.9 26.5 ± 8.2 23.5 ± 7.7  20.9 ± 6.3 24.1 ± 5.4 22.5 ± 6.0 
Progesterone  ng/mL 0.7 ± 0.1 1.3 ± 1.0 1.0 ± 0.7  0.7 ± 0.1 1.1 ± 1.4 0.9 ± 1.0 
17β-Estradiol  pg/mL 41.9 ± 13.7 35.6 ± 40.5 38.7 ± 29.6  33.2 ± 15.6 55.1 ± 39.5 44.1 ± 31.4 
Lipidperoxidation urine         
15-F2t-IsoP  
ng/mg 
creatinine 
1.2 ± 0.5 1.9 ± 0.8 1.5 ± 0.7  1.5 ± 0.6 2.1 ± 0.9 1.8 ± 0.8 
 
a Values represented means ± S.D. All measurements were carried out in plasma or urine and were measured in triplicate. Stars indicate statistical significance (p ≤ 0.05, ANOVA). 
Laboratory diagnosis for reference ranges are: alkaline phosphatase (males: 40-130 U/L, females: 35-105 U/L); osteocalcin (males: 11-70 ng/mL, females: 11-43 ng/mL); Progesterone 
(males: 0.2-1.4 ng/mL, females: 0.2-27 ng/mL depends on the ovulation cycle); 17-β-Estradiol (males: 14-55 pg/mL, females: 30-150 pg/mL depends on the ovulation cycle) (Klinikleitfaden, 
Labordiagnostik, 2007). 
15-F2t-IsoP, 15-F2t isoprostane; 8oxodG, 8-oxo-2´-desoxyguanosine; 8oxoGuo, 8-oxoguanosine 
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Table 4. Impact of consumption of pure with pure XN tablet (n=10) on ROS-
sensitivity and on formation of FPG sensitive sites a 
 
SCGE assay 
(% DNA in tail) 
Start 14d 
H2O2 21.6 ± 1.1 15.6 ± 1.9 *a 
FPGb 13.0 ± 4.0 7.9 ± 2.7 *a 
 
The participants (n = 10, 4 females and 6 males) consumed one XN tablet (12 mg) per 
day over a period of 14 days (for details see Materials and Methods). 
a Values indicate means ± S.D. Stars indicate statistical significance (p ≤ 0.05, 
ANOVA).  
b Values indicate the results obtained after subtraction of the corresponding enzyme 
buffer values from the values obtained after treatment of the nuclei with lesion specific 
enzyme. 
FPG, formamidopyrimidine DNA glycosylase; SCGE, Single cell gel electrophoresis 
assay, XN, xanthohumol. 
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Figure 2A-D. 
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